Advanced Multiscale Inhalation Platforms for Treatment of Pulmonary Diseases Authors: Siyu Zhou, Shasha Ran, Fang Zhang, Haotian Ma, Chunling Jiang, Shanshan Li, Qixiong Zhang Published: 2026 ABSTRACT AbstractPulmonary diseases, including chronic obstructive pulmonary disease, asthma, pneumonia, pulmonary fibrosis, and lung cancer, pose a significant threat to global health. Their high incidence and mortality rates highlight the urgency for novel therapeutic approaches. Traditional treatments such as oral and injection administrations face limitations like first-pass effects, low bioavailability, and systemic toxicity, which restrict their therapeutic efficacy. Inhaled preparations, with advantages such as uniform drug distribution, rapid onset, high bioavailability, and avoidance of hepatic first-pass effects, have become effective means for treating lung diseases. This article reviews the research progress of novel inhaled preparations (nanoparticles, liposomes, microspheres, biomimetic platforms) in treating lung diseases, aiming to explore the development and application of novel inhaled formulations driven by advancements in nanotechnology, biomaterials and preparation processes, thereby providing new possibilities for lung disease treatment. Overall, the research and application prospects of novel inhaled preparations are broad, promising more effective and safer treatment options for patients with pulmonary diseases. Introduction Pulmonary diseases are among the major threats to global health, severely impacting human quality of life and longevity. High-incidence diseases such as chronic obstructive pulmonary disease (COPD),1 asthma,2 pneumonia,3 pulmonary fibrosis,4 and lung cancer5,6 not only cause respiratory difficulties and organ dysfunction but are also closely associated with systemic complications (eg., cardiovascular diseases). For example, COPD is characterized by partially irreversible progressive airflow limitation, primarily caused by abnormal lung inflammation due to long-term exposure to harmful gases or particles (eg., smoking, air pollution). Typical symptoms include chronic cough, sputum production, dyspnea, and recurrent acute exacerbations. Its harmfulness manifests as high mortality, accelerated lung function decline, systemic complications, and significantly reduced quality of life and lifespan due to frequent acute exacerbations.7,8 Idiopathic pulmonary fibrosis (IPF) is another type of lung disease characterized by fibroblast proliferation, excessive extracellular matrix accumulation, accompanied by inflammatory damage and structural destruction, with an average survival of only 3–5 years post-diagnosis.9,10 Survey data indicate that respiratory diseases cause millions of deaths annually, with their high incidence, mortality, and substantial socioeconomic burden underscoring the urgency of prevention and treatment.11 Traditional lung disease treatments primarily rely on oral or injection administration. While they can alleviate symptoms to some extent, they have significant limitations: Oral administration for lung diseases is affected by first-pass effects, leading to low bioavailability and suboptimal efficacy.12 For instance, nintedanib and pirfenidone (PFD) are currently approved drugs for treating IPF,13,14 both exhibiting low oral bioavailability and limited therapeutic potential, requiring higher doses to enhance efficacy, which in turn causes severe hepatic and gastrointestinal toxicity.15,16 Intravenous injection is a systemic administration method where systemic drug distribution leads to non-target organ exposure, causing metabolic burden and adverse reactions,17 such as immunosuppression in hormone therapy18 and nephrotoxicity from intravenous antibiotics.19 Low effective drug concentrations in the lungs necessitate dose increases, exacerbating side effects. For example, intravenous chemotherapy for lung cancer results in drug distribution across various organs, thus requiring high doses to achieve therapeutic concentrations at the lesion site, resulting in severe adverse effects, especially in hair, skin, spleen, and liver that with rapidly dividing cells.20 Additionally, poor patient compliance (particularly in long-term users) further limits the efficacy.21 Therefore, developing more efficient and safe targeted therapeutic strategies is imperative. Inhalation delivery has been considered a promising choice for treating lung diseases because it can shuttle therapeutic payloads directly to lung lesions via simple and noninvasive procedures while reducing systemic toxicity. With uniform drug distribution, rapid onset, high bioavailability, and avoidance of hepatic first-pass effects, inhaled preparations reduce systemic adverse reactions, providing more effective and safer options for lung disease treatment (Figure 1).22–24 Research has shown that the pharmacokinetics and tissue distribution of curcumin (Cur) in rats differ significantly among three routes of administration: inhalation, oral, and intravenous injection.25 After inhalation at 100 mg/kg, the peak concentration (Cmax) of Cur reached 93.15 ng/mL. At the same dose, the bioavailability and Cmax by inhalation were approximately 54-fold and 92-fold higher than those by oral route. Although intravenous injection at a lower dose (2.5 mg/kg) yielded a Cmax of 63.01 ng/mL, the drug was rapidly distributed throughout the body and eliminated quickly. Tissue distribution results further revealed that inhalation led to a pronounced accumulation of Cur in the lung, with extremely low concentrations in the heart, liver, spleen, kidneys, and brain, demonstrating remarkable lung-targeting specificity. However, the drug concentration in lung by intravenous injection was far lower, revealing more significant systemic exposure. Similarly, when sinapine thiocyanate (ST) was formulated as inhaled dry powder for the treatment of acute lung injury (ALI),26 the absolute bioavailability reached as high as 79.12%, approximately 2.7-fold that of the oral route. Overall, inhalation, combining non-invasiveness, lung targeting, and relatively high bioavailability, offers more pronounced advantages. Figure 1Schematic diagram of applications of advanced inhalation platforms.The diagram contrasts traditional therapy with advanced inhalation platforms. Traditional therapy includes oral administration and injection, leading to first-pass effect, low bioavailability, systemic toxicity and poor targeting. Advanced inhalation platforms feature nanoparticles, liposomes, microspheres and biomimetic platforms, offering small particle size, strong penetrability, enhanced drug stability, sustained release and good biocompatibility. The lower section illustrates active targeting, where nanoparticles bind to receptors, undergo internalization and reach cancer cells via endosomes. Stimuli-responsive drug release is shown with stimuli like heat, pH, redox and enzyme activity triggering drug release.Diagram comparing traditional therapy and advanced inhalation platforms for drug delivery. Schematic diagram of applications of advanced inhalation platforms. In recent years, with advancements in nanotechnology, biomaterials, and preparation processes, novel inhaled preparations continue to emerge, offering new possibilities for lung disease treatment.27–30 This article aims to review the latest research progress in inhaled preparations for treating lung diseases, focusing on the development and application of novel inhaled formulations, to provide references for related research and clinical practice. Advanced Inhalation Platforms for Pulmonary Diseases Nanoparticles Active Targeting Nanocarriers Active targeting nanocarriers refer to nanocarriers modified or designed to actively recognize and bind to target cells or tissues, achieving precise drug delivery. Active targeting strategies are based on the specific receptors on cell surface. For instance, tumor cells overexpress specific receptors like folate (FA) receptor,31 transferrin (Tf) receptor,32 and epidermal growth factor receptor (EGFR).33 By modifying nanocarrier surfaces with ligands that specifically bind these receptors enabling active targeting.34 An EGFR-targeted nanoparticles (EGFC/DLPNs) co-delivering cisplatin and doxorubicin was developed for lung carcinoma therapy. In vitro and in vivo results showed good stability, sustained drug release, significant anticancer effects and low toxicity.35 Another smart chitosan-PLGA nanocarrier (CPSF) functionalized with FA ligands was developed for targeted delivery of sorafenib (SRF) to lung cancer cells. CPSF efficiently accumulated in cancer tissues bypassing cancer cell membrane barriers through high-affinity binding to FA receptors, thus reducing systemic distribution, increasing cytotoxic doses to tumor cells and minimizing inhibition of normal cells.36 Researchers anchored Tf to nanomicelle surfaces through the coordination effect between surface carboxyl groups and Fe3+ to develop an inhalable nanomimosa (Tf-Mic@SD) to enhance ferroptosis therapy for lung cancer based on lysosome hijacking strategy (Figure 2).37 The Fenton-like reaction substrate dihydroartemisinin (DHA) and SRF were further encapsulated. After inhalation, Tf-Mic@SD is captured by tumor cells through Tf receptor recognition, then endocytosed by lysosomes. Under acidic conditions, the conformation of Tf changes, releasing Fe3+, DHA, and SRF, triggering Fenton-like reactions to rapidly generate reactive oxygen species, accelerating ferroptosis and effectively eliminating tumor cells. Results showed Tf-Mic@SD effectively inhibited lung tumor growth with good biosafety for normal cells, offering new methods for lung cancer treatment and potential application in other Tf recepter-high cancers. Figure 2(A) Tf-Mic@SD presents a schematic of the optimized ferroptosis-based therapy for lung cancer; (B) H&E-stained sections of lung tumor tissue.37 Reprinted with permission from Journal of Controlled Release, 386 (2025) 114101. Copyright 2025, with permission from Elsevier.The image A shows a schematic of the optimized ferroptosis-based therapy for lung cancer. It begins with PLGA-PEG-COOH dissolving and forming a thin-film dispersion with DHA and SRF. This is followed by Tf modification and pH adjustment, leading to lung cancer targeting. The process involves recognition and capture by tumor cells, lysosome hijacking, ROS accumulation and rapid in situ ROS generation, leading to apoptosis, ferroptosis and LPO accumulation. The inset shows the lysosomal acidic environment releasing Fe superscript 3 plus, triggering a Fenton-like reaction to produce ROS. The image B shows H&E-stained sections of lung tissue from healthy, control, Mic@S, Mic@D, Mic@SD and Tf-Mic@SD groups, illustrating the effects of different treatments on lung cancer tissue.Schematic of ferroptosis-based lung cancer therapy and H&E-stained lung tissue sections showing treatment effects. (A) Tf-Mic@SD presents a schematic of the optimized ferroptosis-based therapy for lung cancer; (B) H&E-stained sections of lung tumor tissue.37 Reprinted with permission from Journal of Controlled Release, 386 (2025) 114101. Copyright 2025, with permission from Elsevier. Targeting peptides, which are able to recognize and bind to specific cell or tissue surface receptors, is another kind of anchor to modify the nanoparticles for enhancing targeting.38 A neonatal-Fc-receptor-targeted peptide (FcBP) was anchored on polyethylene glycol (PEG) nanoparticles (PEG-NP) to form FcBP-NP for ameliorated transepithelial transport and prolonged pulmonary retention.39 By FcBP-functionalization, the mucus-permeability of PEG-NP was not impaired. Moreover, the cellular internalization and exocytosis via specific receptor-mediated processes were enhanced. Loaded with dexamethasone (Dex), FcBP-NP@Dex could effectively cross the airway epithelial layer and be endocytosed by inflammatory cells, then significantly reduce inflammatory cytokine levels and relieve asthma symptoms (Figure 3). This study provided a promising strategy for inhalation therapy with prolonged pulmonary retention of drugs. Figure 3(A) Schematic illustration of FcBP-NP@Dex to ameliorate airway inflammation in asthma. (B) Uptake of transported nanoparticles by RAW 264.7 cells. (C) Uptake of nanoparticles and mucin. **p < 0.01. Mean ± SD, n = 3. (D) Apparent permeability (Papp) values of nanoparticles in expectorated human sputum. ns p > 0.05, **p < 0.01. Mean ± SD, n = 3.39 Reprinted with permission from Journal of Controlled Release, 367 (2024) 223–234. Copyright 2024, with permission from Elsevier.The composite image consists of four parts. A) Diagram illustrating FcBP-NP@Dex nanoparticles targeting airway inflammation in asthma. It shows PLGA NP, SPC, DSPE-PEG-FcBP and Dex components. The nanoparticles interact with the airway, reducing hyperresponsiveness, inflammation and excessive mucus. Inflammatory cells show decreased TNF-alpha and IL-10 levels. Receptor-mediated endocytosis involves FcRn, EE, Golgi, ER and nucleus. B) Microscopy images showing DAPI, C6 and merged views of PEG-NP@C6 and FcBP-NP@C6. C) Bar graph comparing the percentage of aggregates for PEG-NP@C6, FcBP-NP@C6 and PVA-NP@C6, with ns indicating no significant difference and indicating p < 0.01. D) Bar graph showing apparent permeability (Papp) values in x 10 superscript -6 cm/s for PEG-NP@C6, FcBP-NP@C6 and PVA-NP@C6, with ns indicating no significant difference and indicating p < 0.01.Composite image showing nanoparticle uptake, airway inflammation, cell imaging and permeability data. (A) Schematic illustration of FcBP-NP@Dex to ameliorate airway inflammation in asthma. (B) Uptake of transported nanoparticles by RAW 264.7 cells. (C) Uptake of nanoparticles and mucin. **p < 0.01. Mean ± SD, n = 3. (D) Apparent permeability (Papp) values of nanoparticles in expectorated human sputum. ns p > 0.05, **p < 0.01. Mean ± SD, n = 3.39 Reprinted with permission from Journal of Controlled Release, 367 (2024) 223–234. Copyright 2024, with permission from Elsevier. Stimulus-Responsive Nanoparticles Responsive nanocarriers are nanomaterials that alter their properties in response to external environmental changes (eg., pH, temperature, magnetic fields, enzymes) or specific physiological/pathological signals, enabling targeted drug delivery and controlled release.40,41 The tumor microenvironment features low pH, enhanced enzyme activity (eg., MMP-2, cathepsin B), and altered redox status (ROS/GSH imbalance), supporting stimulus-responsive nanoparticles in cancer therapy.42,43 An inhalable pH-responsive core-shell nanocarrier (PEG-CS/Alg@MSNs) for sequential release of drugs in lung cancer therapy was established via layer-by-layer self-assembly.44 In this study, aminated mesoporous silica (MSNs) loaded with docetaxel (DTX) was used as a core, then sequentially coated with polyanionic alginate (Alg) as an intermediary sellotape layer to prevent drug leaking. The outermost shell is polycationic PEGylated-chitosan (PEG-CS) loaded with gemcitabine (GMC). Under neutral to weakly acidic physiological conditions, the PEG-CS and Alg layers prevent premature drug release and ensure the stability of the nanocarrier; while in the acidic environment of the tumor microenvironment, the amino groups in chitosan undergo protonation, destroying the shell structure, thereby triggering the rapid release of GMC, followed by the slow release of DTX from MSNs. Experimental results showed the good lung deposition, biosafety and significant anticancer effects of PEG-CS/Alg@MSNs on A549 cells, providing a new and effective drug delivery system for lung cancer treatment. Besides, an inhalable mucoadhesive proteinic nanoparticles with redox responsibility were conducted to realize noninvasive, localized treatment of lung cancer in a highly biocompatible, site-specific manner. Specifically, the thiolated mussel adhesive protein (thMAP) containing 3,4-dihydroxyphenylalanine (DOPA) based nanoparticles (thMAP NPs) were administered to target lung tissues via nebulization process. Cur-loaded thMAP NPs (thMAP@Cur NPs) showed efficient cellular uptake through the thiol-mediated pathway and controlled intracellular release of Cur in response to the high glutathione (GSH) concentration in tumor microenvironment (Figure 4).45 This study proposes a novel precision therapy strategy for lung cancer that addresses the poor mucosal absorption of hydrophobic drugs in traditional inhalation by enabling efficient local pulmonary delivery and long-term retention, reducing systemic toxicity, while a redox-specific response mechanism enhances intracellular drug release efficiency and therapeutic outcomes, indicating broad application potential. Figure 4(A) Schematic illustration of the inhalable thMAP@Cur NPs for targeted lung cancer therapy. (B) In vitro fluorescence images of lung tissue at 1, 5, and 10 days after nebulization. Rhodamine-labeled BSA and MAP NPs were used as controls. (C) The integrated fluorescence intensity of the resected lung tissue area. (D) Optical images of lung tissue resected at the end of the study. The blue arrow indicates the tumor. (E) H&E and CD31 staining images of lung tissues. Blue arrows indicate metastatic melanoma nodules, red arrows denote epithelial hyperplasia. Green represents CD31-positive cells, blue indicates nuclei (DAPI). (F) Relative tumor area (tumor area/total area). Data represent mean ± s.e.m. (n ≥ 5), with statistical significance indicated by **p < 0.01 and ***p < 0.005.45 Reprinted with permission from Biomaterials, 316 (2025) 123004. Copyright 2025, with permission from Elsevier.This multi-panel infographic illustrates the use of nebulized thMAP@Cur nanoparticles (NPs) for targeted lung cancer therapy. Image A shows the nebulization process and how thMAP@Cur NPs adhere to mucus and release Cur in high GSH environments within lung tumor cells. Image B presents fluorescence images of lung tissue at days 1, 5 and 10, comparing BSA NPs, MAP NPs and thMAP@Cur NPs. Image C graphs fluorescence intensity over time, showing thMAP@Cur NPs maintain higher intensity. Image D displays optical images of lung tissue, highlighting tumor regions. Image E shows H&E and CD31 staining, indicating metastatic melanoma nodules and epithelial hyperplasia. Image F compares relative tumor areas, with thMAP@Cur NPs showing the smallest tumor area, indicating effectiveness. Statistical significance is noted with asterisks.Nebulized thMAP@Cur NPs enhance lung cancer treatment by targeting tumors and reducing burden. (A) Schematic illustration of the inhalable thMAP@Cur NPs for targeted lung cancer therapy. (B) In vitro fluorescence images of lung tissue at 1, 5, and 10 days after nebulization. Rhodamine-labeled BSA and MAP NPs were used as controls. (C) The integrated fluorescence intensity of the resected lung tissue area. (D) Optical images of lung tissue resected at the end of the study. The blue arrow indicates the tumor. (E) H&E and CD31 staining images of lung tissues. Blue arrows indicate metastatic melanoma nodules, red arrows denote epithelial hyperplasia. Green represents CD31-positive cells, blue indicates nuclei (DAPI). (F) Relative tumor area (tumor area/total area). Data represent mean ± s.e.m. (n ≥ 5), with statistical significance indicated by **p < 0.01 and ***p < 0.005.45 Reprinted with permission from Biomaterials, 316 (2025) 123004. Copyright 2025, with permission from Elsevier. The management of severe bacterial pneumonia remains a formidable clinical problem, primarily due to the compromised antibiotic efficacy resulting from the obstructive mucus barrier in the lower respiratory tract. A nano-agent (OTP) containing natural polysaccharide oxidized soluble starch (OSS), tobramycin (TOB) and m-PEG-NH2, with mucus-penetrating and infection-responsive releasing capabilities, was designed and fabricated (Figure 5).46 Due to its hydrophilicity, small molecular size, and positively charged surface, OTP exhibits enhanced mucosal permeability, enabling it to overcome mucociliary clearance and reach pulmonary lesions. Then TOB was responsively released by the triggering of slightly acidic environment of infection (pH = 5.4), owning to the pH-sensitive imine bond. The efficacy of OTP was further validated in a pneumonia mice model. This study presents a versatile and effective strategy for constructing inhalable drug delivery systems to treat pneumonia, highlighting its considerable potential for clinical management of severe pulmonary infections. Other researches on the treatment of lung diseases by inhalable nanoparticle systems were summarized in Table 1. Figure 5(A) Schematic diagram illustrating the preparation process of OTP21 and its application in suppressing pulmonary infection therapy. (B) pH-responsive release kinetics of TOB from OTP21 and OTP21-R. (C) Images of OTP21 and OT21 samples penetrating artificial mucus. (D) Bioluminescence images of mice at day 1 and day 3 (“×” indicates death of the experimental animal due to infection). (E) Bacterial colonies from lung homogenates from Staphylococcus aureus-infected lung tissues. (F) Lung tissues collected from mice sacrificed 72 hours post-bacterial challenge, subjected to histological analysis via H&E staining and immunohistochemical (IHC) staining.46 Reprinted with permission from Nano Today, 44 (2022) 44. Copyright 2022, with permission from Elsevier.The composite image highlights OTP21′s application. A) OTP21 preparation uses SS, OSS, TOB and mPEG-NH2 to bypass the mucus barrier in the lower respiratory tract, ensuring stable TOB release at pH 7.4 and responsive release at pH 5.4 via nebulization for infection targeting. B) A graph shows TOB release over time, comparing OTP21 and OTP21-R at varying pH levels, with ′Time (h)′ on the x-axis and ′TOB release ratio (%)′ on the y-axis. C) Images illustrate OTP21 and OT21 samples penetrating artificial mucus from 0 to 120 minutes. D) Bioluminescence images of mice on days 1 and 3 display radiance levels, with ′×′ marking death from infection. E) Lung homogenate images compare bacterial colonies in untreated, TOB, OTP21 and healthy control samples. F) Histological lung tissue analysis using H&E and IL-1β (IHC) staining reveals differences among untreated, TOB, OTP21 and healthy control samples.Image of OTP21 prep, TOB release, mucus penetration, bioluminescence, bacteria and lung histology. Table 1Summary of Inhalable Nanoparticles for Treating Pulmonary DiseasesDiseasesDrugsCarriersRemarksSARS-CoV-2 caused pneumonia47ClofoctolPLGA-based NPsImproved low solubility and potential toxicityALI48Poly(EGCG), BaicalinHyaluronic acid-modified poly(EGCG)-baicalin NPsSelectively targeted M1-type alveolar macrophages through CD44 receptor interactionsALI49DexamethasonePCL-ss-PSBMAMucus barrier penetration benefited from zwitterionic groupsGSH-triggered drug release benefited from disulfide bondsPneumococcal pneumonia50Levofloxacin (LVX), Catalase (CAT)LVX-loaded CAT-tannic acid (TA) nano-assembliesTA mediated mucoadhesionCAT decomposed the accumulated H2O2LVX used as antibioticLung metastases51STING agonist cyclic GMP-AMP (cGAMP)Hyaluronic acid (HA)-lipid hybrid multilamellar NPs encapsulating cGAMP (HLHC)Multilamellar structure enhanced mechanical rigidityHA surface coating enhanced mucus penetrationArginine-modification exhibited effective delivery for cGAMPALI52DexamethasonePhosphatidylserine (PtdSer) decorated poly(lactic-co-glycolic acid) NPsPtdSer decoration endows anti-inflammatory function to nanocarriersIncreased accumulation of NPs in lung macrophagesPneumonia caused by carbapenem resistant Klebsiella pneumoniae53Polymyxin B (PMB)PMB-loaded albumin NPs with surface modification of acid-responsive functional molecule (PEBA) and NH2-PEG-SH (PEG-pHSA@PMB)Sulfhydryl groups of PEG-pHSA@PMB interacting with mucins help penetrate mucusControlled release of PMB in acid microenvironmentNotes: All studies presented in this table are preclinical. (A) Schematic diagram illustrating the preparation process of OTP21 and its application in suppressing pulmonary infection therapy. (B) pH-responsive release kinetics of TOB from OTP21 and OTP21-R. (C) Images of OTP21 and OT21 samples penetrating artificial mucus. (D) Bioluminescence images of mice at day 1 and day 3 (“×” indicates death of the experimental animal due to infection). (E) Bacterial colonies from lung homogenates from Staphylococcus aureus-infected lung tissues. (F) Lung tissues collected from mice sacrificed 72 hours post-bacterial challenge, subjected to histological analysis via H&E staining and immunohistochemical (IHC) staining.46 Reprinted with permission from Nano Today, 44 (2022) 44. Copyright 2022, with permission from Elsevier. Table 1Summary of Inhalable Nanoparticles for Treating Pulmonary DiseasesDiseasesDrugsCarriersRemarksSARS-CoV-2 caused pneumonia47ClofoctolPLGA-based NPsImproved low solubility and potential toxicityALI48Poly(EGCG), BaicalinHyaluronic acid-modified poly(EGCG)-baicalin NPsSelectively targeted M1-type alveolar macrophages through CD44 receptor interactionsALI49DexamethasonePCL-ss-PSBMAMucus barrier penetration benefited from zwitterionic groupsGSH-triggered drug release benefited from disulfide bondsPneumococcal pneumonia50Levofloxacin (LVX), Catalase (CAT)LVX-loaded CAT-tannic acid (TA) nano-assembliesTA mediated mucoadhesionCAT decomposed the accumulated H2O2LVX used as antibioticLung metastases51STING agonist cyclic GMP-AMP (cGAMP)Hyaluronic acid (HA)-lipid hybrid multilamellar NPs encapsulating cGAMP (HLHC)Multilamellar structure enhanced mechanical rigidityHA surface coating enhanced mucus penetrationArginine-modification exhibited effective delivery for cGAMPALI52DexamethasonePhosphatidylserine (PtdSer) decorated poly(lactic-co-glycolic acid) NPsPtdSer decoration endows anti-inflammatory function to nanocarriersIncreased accumulation of NPs in lung macrophagesPneumonia caused by carbapenem resistant Klebsiella pneumoniae53Polymyxin B (PMB)PMB-loaded albumin NPs with surface modification of acid-responsive functional molecule (PEBA) and NH2-PEG-SH (PEG-pHSA@PMB)Sulfhydryl groups of PEG-pHSA@PMB interacting with mucins help penetrate mucusControlled release of PMB in acid microenvironmentNotes: All studies presented in this table are preclinical. Summary of Inhalable Nanoparticles for Treating Pulmonary Diseases Improved low solubility and potential toxicity Improved low solubility and potential toxicity Selectively targeted M1-type alveolar macrophages through CD44 receptor interactions Selectively targeted M1-type alveolar macrophages through CD44 receptor interactions Mucus barrier penetration benefited from zwitterionic groups Mucus barrier penetration benefited from zwitterionic groups GSH-triggered drug release benefited from disulfide bonds GSH-triggered drug release benefited from disulfide bonds TA mediated mucoadhesion TA mediated mucoadhesion CAT decomposed the accumulated H2O2 CAT decomposed the accumulated H2O2 LVX used as antibiotic LVX used as antibiotic Multilamellar structure enhanced mechanical rigidity Multilamellar structure enhanced mechanical rigidity HA surface coating enhanced mucus penetration HA surface coating enhanced mucus penetration Arginine-modification exhibited effective delivery for cGAMP Arginine-modification exhibited effective delivery for cGAMP PtdSer decoration endows anti-inflammatory function to nanocarriers PtdSer decoration endows anti-inflammatory function to nanocarriers Increased accumulation of NPs in lung macrophages Increased accumulation of NPs in lung macrophages Sulfhydryl groups of PEG-pHSA@PMB interacting with mucins help penetrate mucus Sulfhydryl groups of PEG-pHSA@PMB interacting with mucins help penetrate mucus Controlled release of PMB in acid microenvironment Controlled release of PMB in acid microenvironment Notes: All studies presented in this table are preclinical. Liposomes Inhaled liposomes are microcapsules composed of phospholipid bilayers, capable of encapsulating both hydrophilic and hydrophobic drugs. They have good biocompatibility, can protect drugs from degradation, and achieve sustained release. In recent years, the potential of liposome technology in the treatment of pulmonary diseases has been continuously explored. Research has found that liposomes composed of saturated neutral and anionic phospholipids possessed high stability and permeability.54 The following will introduce several innovative studies based on liposomes, which explore from different perspectives how to enhance drug delivery efficiency and therapeutic effect through liposome technology. Alveolar macrophages (AMs) possess a unique ability to infiltrate tumor tissue and play an important role in pulmonary metastasis. Specifically, AMs are prone to be polarized into immunosuppressive M2 phenotype in pulmonary metastasis, while immune-promoting M1 phenotype is effective in immunotherapy. Based on the capacity of AMs for non-specific phagocytosis and the specific binding with phosphatidylserine on the surface of apoptotic cell, a phosphatidylserine-decorated liposome was fabricated for both passive and active targeted delivery of TLR7/8 agonists (R848) and SHP2 inhibitor (SHP099), which could polarize AMs into immune-promoting M1 phenotype and restore the phagocytosis.55 This kind of inhalable and AM targeted immunostimulants (I-AM-IMs) could promote the phagocytic elimination of pulmonary metastatic tumor cells and activate CD8+ T cell specific anti-tumor immunity through phenotype reprogramming of AMs, then eradicate pulmonary metastasis. Given the high collagen content in IPF lesions, collagen-targeted drug delivery systems can be used for the treatment of IPF. A pathological collagen targeting and penetrating liposome (DP-CC) for delivery of anti-fibrotic dual drugs including pirfenidone (PFD) and dexamethasone (DEX) have been constructed (Figure 6). With co-decoration of collagen binding peptide (CBP) and collagenase (COL) on the surface of DP-CC, the vehicle could efficiently target the fibrotic lesions and break through the collagen barrier then deep deliver to the injured alveoli. Subsequently, the released PFD and DEX exhibited a synergistic anti-fibrotic effect, capable of repairing damaged epithelial tissues and remodeling the extracellular matrix, thereby reconstructing the lung structure.56 Figure 6Pathological collagen targeting and penetrating liposomes (DP-CC) for deep injured alveoli drug delivery. (A) Components and construction of the DP-CC. (B) Proposed mechanism of the DP-CC in vivo. i) Pathological collagen is exposed to the bloodstream around fibrotic sites, DP-CC targeted the pathological collagen and delivered PFD/DEX to the fibrotic lungs through intravenous injection. ii) Pathological collagen is accumulated to obstruct foreign liposomes, while DP-CC could break through the collagen barrier. iii) After reaching the deep injured alveoli, PFD and DEX exert a synergistic anti-fibrotic effect to reverse IPF.56 Reprinted with permission from Journal of Controlled Release, 351 (2022) 623–637. Copyright 2022, with permission from Elsevier.The diagram consists of two parts. A shows the construction of DP-CC. Ingredients include soy lecithin, cholesterol, DSPE-PEG-MAL, dexamethasone and pirfenidone, which self-assemble into DP. Collagen binding peptide and collagenase are added to form DP-CC. B illustrates the mechanism of DP-CC in reversing IPF. It compares BLM-induced respiratory restriction with DP-CC-induced respiratory recovery. The process involves intravenous DP-CC targeting collagen, penetrating the collagen barrier and enhancing anti-fibrotic effects. This leads to ECM remodeling and improved gas exchange in alveoli, reversing IPF.Diagram: DP-CC construction, IPF reversal via collagen-targeting, penetrating liposomes. Pathological collagen targeting and penetrating liposomes (DP-CC) for deep injured alveoli drug delivery. (A) Components and construction of the DP-CC. (B) Proposed mechanism of the DP-CC in vivo. i) Pathological collagen is exposed to the bloodstream around fibrotic sites, DP-CC targeted the pathological collagen and delivered PFD/DEX to the fibrotic lungs through intravenous injection. ii) Pathological collagen is accumulated to obstruct foreign liposomes, while DP-CC could break through the collagen barrier. iii) After reaching the deep injured alveoli, PFD and DEX exert a synergistic anti-fibrotic effect to reverse IPF.56 Reprinted with permission from Journal of Controlled Release, 351 (2022) 623–637. Copyright 2022, with permission from Elsevier. In addition to the above two innovative strategies, the basic liposome drug delivery system also demonstrates great potential. The effect of liposomal prostaglandin E2 (PGE2) delivered by inhalation in the treatment of IPF was studied.57 In a murine model, the therapeutic potential of pulmonary-delivered liposomal PGE2 was assessed. Inhalation led to greater lung-specific accumulation and less systemic distribution compared to intravenous administration. Experimental results demonstrated that liposomal PGE2 significantly attenuated inflammation and fibrotic damage in lung tissue, prevented weight loss, reduced hydroxyproline accumulation, and markedly reduced mortality in mice. These findings indicate that pulmonary delivery of liposomal PGE2 via inhalation is an effective therapeutic approach for IPF. This study provides critical evidence supporting the development of novel IPF treatments, particularly by enhancing local drug concentrations while mitigating systemic side effects. Although inhaled lipid-based delivery systems hold significant promise for IPF treatment, their applicability extends beyond this condition. Ongoing research explores their potential for other pulmonary diseases to benefit broader patient populations. For instance, Jiang et al58 proposed an innovative inhaled lipid-based strategy for treating ALI and its progression to acute respiratory distress syndrome (ARDS). Recognizing the central role of macrophages, particularly pro-inflammatory M1 polarization, in the pathogenesis of ALI/ARDS, the researchers designed L-arginine-modified liposomes targeting M1 macrophages via their highly expressed CAT-2 receptors. Curcumin was encapsulated as a model drug (Figure 7). The modification was achieved by conjugating L-arginine’s carboxyl groups to liposomal amines via EDC/NHS chemistry. Results demonstrated that this targeted system significantly enhanced curcumin’s efficacy against ALI/ARDS. By enabling direct lung deposition, it bypasses hepatic/splenic first-pass metabolism, increases local drug concentration, and minimizes systemic adverse effects. This approach offers novel insights for treating acute pulmonary inflammation, including cytokine storms associated with COVID-19, presenting a safer and more effective therapeutic option. Figure 7(A) Preparation of Arg-Cur-Lip and its treatment for ALI/ARDS. L-arginine functionalized Cur-Lip was used to target M1 macrophages in the lung after aerosol inhalation and release the drug for treatment after accumulation in the inflamed lung. (B) In vivo fluorescence images of a rat ALI model using DiR loaded liposomes via pulmonary nebulization. (C) In vitro fluorescence images of excised organs 24 hours after using DiR loaded liposomes. Measure the protein expression levels of TNF-α (D) and IL-6 (E) in lung tissue using ELISA.58 Data are represented as means ± SD (n = 4). *P < 0.05 compared with the model group, **P < 0.01 compared with the model group, ##P < 0.01 compared with the control group, &P < 0.05 compared with Cur-Lip group. Reprinted with permission from European Journal of Pharmaceutics and Biopharmaceutics, 182 (2023) 21–31. Copyright 2023, with permission from Elsevier.An infographic illustrating targeted liposomal curcumin delivery to lungs for reducing inflammation. The schematic shows Arg-Cur-Lip preparation targeting CAT-2B receptors on M1 macrophages, leading to anti-inflammatory effects. In vivo fluorescence images display DiR-Lip and Arg-DiR-Lip accumulation in rats over 4, 12 and 24 hours, highlighting stronger lung accumulation with Arg-DiR-Lip. Ex vivo images show fluorescence in organs like lung, liver and kidney, with Arg-DiR-Lip showing higher intensity. Bar graphs depict TNF-α and IL-6 concentrations in pg/mL across groups: Control, Model, Dex-Na, Cur-Lip and Arg-Cur-Lip. TNF-α levels are highest in Model, reduced in Dex-Na, Cur-Lip and lowest in Arg-Cur-Lip. IL-6 follows a similar trend. Significance markers indicate statistical differences: ##, * and &. The flow is from preparation to in vivo imaging, ex vivo organs and cytokine quantification.Arg-Cur-Lip for lung inflammation: prep, imaging, cytokine reduction. (A) Preparation of Arg-Cur-Lip and its treatment for ALI/ARDS. L-arginine functionalized Cur-Lip was used to target M1 macrophages in the lung after aerosol inhalation and release the drug for treatment after accumulation in the inflamed lung. (B) In vivo fluorescence images of a rat ALI model using DiR loaded liposomes via pulmonary nebulization. (C) In vitro fluorescence images of excised organs 24 hours after using DiR loaded liposomes. Measure the protein expression levels of TNF-α (D) and IL-6 (E) in lung tissue using ELISA.58 Data are represented as means ± SD (n = 4). *P < 0.05 compared with the model group, **P < 0.01 compared with the model group, ##P < 0.01 compared with the control group, &P < 0.05 compared with Cur-Lip group. Reprinted with permission from European Journal of Pharmaceutics and Biopharmaceutics, 182 (2023) 21–31. Copyright 2023, with permission from Elsevier. Other researches on the treatment of lung diseases by inhalable liposomal preparations were summarized in Table 2. Table 2Summary of Inhalable Liposomal Preparations for Treating Pulmonary DiseasesDiseasesDrugsLiposome ComponentsRemarksIPF59Verteporfin (VER), pirfenidone (PFD)Phospholipid, cholesterol, DSPE-mPEG2000, PFD, VERDual drug-loaded liposomes inhibited airway epithelium fluidization and fibroblast overactivationIPF60ZerumboneOleic acid, dipalmitoylphosphatidyl-choline, cholesterol, zerumboneEnhanced drug solubilityAcid-responsive drug release at the site of lung fibrosisIPF61Dimethyl fumarate (Nrf2 agonist)DPPC, DSPE-TK-PEG2000, cholesterol, dimethyl fumarateGood biocompatibilityROS-responsibilityProlonged retention time in lungsIPF62Nintedanib, S-allylmercapto-N-acetylcysteine (ASSNAC)Phospholipid, cholesterol, DSPE-PEG2000, Nintedanib, ASSNACEnhanced permeability of mucusPrevent phagocytosis of macrophagesIncrease retention time and concentration of drugs in lungALI63BergaptenDPPC, cholesterol, DSPE-mPEG2000, BergaptenAmeliorating ALI via orchestrating M1/M2 macrophage polarizationSuppressing proinflammatory signals and inhibiting activation of TLR4-MyD88-NF-κB pathwayALI64PachypodolDPPC, cholesterol, DSPE-mPEG2000, PachypodolAlleviating lung injury and repair lung epithelial and vascular endothelial barriers via inhibiting the activation of TLR4-MyD88-NF-κB/MAPK signaling pathwayBronchiolitis obliterans syndrome (NCT03657342)65Cyclosporine ADPPC, cholesterol1. Directly delivering liposomal cyclosporine A to the transplanted lung via inhalation Precisely inhibiting local rejection and reducing the systemic side effects of cyclosporine AChronic pulmonary aspergillosis (NCT07530263)66Amphotericin BHSPC, cholesterol, DSPGTargeted therapy drug deliveryReduce systemic toxicityNotes: Studies with a clinical trial number provided are clinical studies; those without are preclinical studies. Table 2Summary of Inhalable Liposomal Preparations for Treating Pulmonary DiseasesDiseasesDrugsLiposome ComponentsRemarksIPF59Verteporfin (VER), pirfenidone (PFD)Phospholipid, cholesterol, DSPE-mPEG2000, PFD, VERDual drug-loaded liposomes inhibited airway epithelium fluidization and fibroblast overactivationIPF60ZerumboneOleic acid, dipalmitoylphosphatidyl-choline, cholesterol, zerumboneEnhanced drug solubilityAcid-responsive drug release at the site of lung fibrosisIPF61Dimethyl fumarate (Nrf2 agonist)DPPC, DSPE-TK-PEG2000, cholesterol, dimethyl fumarateGood biocompatibilityROS-responsibilityProlonged retention time in lungsIPF62Nintedanib, S-allylmercapto-N-acetylcysteine (ASSNAC)Phospholipid, cholesterol, DSPE-PEG2000, Nintedanib, ASSNACEnhanced permeability of mucusPrevent phagocytosis of macrophagesIncrease retention time and concentration of drugs in lungALI63BergaptenDPPC, cholesterol, DSPE-mPEG2000, BergaptenAmeliorating ALI via orchestrating M1/M2 macrophage polarizationSuppressing proinflammatory signals and inhibiting activation of TLR4-MyD88-NF-κB pathwayALI64PachypodolDPPC, cholesterol, DSPE-mPEG2000, PachypodolAlleviating lung injury and repair lung epithelial and vascular endothelial barriers via inhibiting the activation of TLR4-MyD88-NF-κB/MAPK signaling pathwayBronchiolitis obliterans syndrome (NCT03657342)65Cyclosporine ADPPC, cholesterol1. Directly delivering liposomal cyclosporine A to the transplanted lung via inhalation Precisely inhibiting local rejection and reducing the systemic side effects of cyclosporine AChronic pulmonary aspergillosis (NCT07530263)66Amphotericin BHSPC, cholesterol, DSPGTargeted therapy drug deliveryReduce systemic toxicityNotes: Studies with a clinical trial number provided are clinical studies; those without are preclinical studies. Summary of Inhalable Liposomal Preparations for Treating Pulmonary Diseases Dual drug-loaded liposomes inhibited airway epithelium fluidization and fibroblast overactivation Dual drug-loaded liposomes inhibited airway epithelium fluidization and fibroblast overactivation Enhanced drug solubility Enhanced drug solubility Acid-responsive drug release at the site of lung fibrosis Acid-responsive drug release at the site of lung fibrosis Good biocompatibility Good biocompatibility ROS-responsibility ROS-responsibility Prolonged retention time in lungs Prolonged retention time in lungs Enhanced permeability of mucus Enhanced permeability of mucus Prevent phagocytosis of macrophages Prevent phagocytosis of macrophages Increase retention time and concentration of drugs in lung Increase retention time and concentration of drugs in lung Ameliorating ALI via orchestrating M1/M2 macrophage polarization Ameliorating ALI via orchestrating M1/M2 macrophage polarization Suppressing proinflammatory signals and inhibiting activation of TLR4-MyD88-NF-κB pathway Suppressing proinflammatory signals and inhibiting activation of TLR4-MyD88-NF-κB pathway Alleviating lung injury and repair lung epithelial and vascular endothelial barriers via inhibiting the activation of TLR4-MyD88-NF-κB/MAPK signaling pathway Alleviating lung injury and repair lung epithelial and vascular endothelial barriers via inhibiting the activation of TLR4-MyD88-NF-κB/MAPK signaling pathway Precisely inhibiting local rejection and reducing the systemic side effects of cyclosporine A Precisely inhibiting local rejection and reducing the systemic side effects of cyclosporine A Targeted therapy drug delivery Targeted therapy drug delivery Reduce systemic toxicity Reduce systemic toxicity Notes: Studies with a clinical trial number provided are clinical studies; those without are preclinical studies. Microspheres Microsphere inhalation agents are a new type of drug delivery system, where drugs are precisely encapsulated within microsphere carriers constructed from biodegradable polymers.67 Their core advantage lies in the precise control over particle size, which ensures targeted pulmonary deposition at lesion sites following inhalation. This facilitates local drug enrichment, thereby enhancing therapeutic efficacy while minimizing off-target side effects.68 Furthermore, inhaled microspheres exploit a distinctive sustained-release mechanism based on the gradual degradation of polymeric matrices within the physiological environment.69 This process ensures continuous and stable drug elution, sustaining effective drug concentrations in the lungs over extended periods. Consequently, it prolongs the duration of pharmacological action and reduces dosing frequency, which may enhance patient compliance. These attributes underscore the significant clinical potential of microsphere-based systems for pulmonary diseases, offering innovative strategies for precision medicine.70,71 In the investigation of inhalable microspheres for pulmonary diseases, Cheng et al developed an aerosol platform of inhalable honeycomb-shaped microsphere (HCLplga-Ab) composed of FDA-approved PLGA and pore-forming agent for the targeted delivery of Andrographolide, a bioactive compound derived from traditional Chinese medicine. The microsphere was coated by chitosan-ambroxol to facilitate mucosal penetration, sequential drug release, and prolonged lung retention (Figure 8). Characterization revealed a geometric diameter of ~10–15 μm and an aerodynamic diameter of ~2.57 μm, enabling deep lung deposition while evading alveolar macrophage clearance. In murine models of ALI, bacterial pneumonia, and fungal pneumonia, the aerosol exhibited potent mucosal penetration and biofilm destruction capabilities, markedly reducing inflammation and pathogen loads while improving survival rates. Notably, compared with conventional PLGA microspheres, the HCLplga-Ab variant demonstrated staged release kinetics: ambroxol was released first to compromise the mucosal barrier, followed by sustained Andrographolide release to exert anti-inflammatory and antibacterial effects. This work presents a novel strategy integrating traditional medicine with advanced aerosol technology, highlighting significant translational potential for treating respiratory diseases such as pneumonia, asthma, and pulmonary fibrosis.72 Figure 8Schematic illustration of a honeycomb-inspired porous microsphere as an inhalable drug delivery platform. (A) Particle deposition in the respiratory tract depends on aerodynamic size, which is tunable by adjusting microsphere porosity, enabling targeted lung delivery. (B) Sequential drug release: The inhalable dry powder aerosol penetrates the mucus barrier and disrupts biofilms during the first phase, followed by anti-inflammatory and antibacterial effects in the second phase.72 Reprinted with permission from Biomaterials, 322 (2025) 123401. Copyright 2025, with permission from Elsevier.Image A illustrates particle distribution in the respiratory system during breathing. Inhalation: 0.1 micrometer particles reach alveoli, 2.5 micrometer particles reach lungs and 10 micrometer particles reach the mouth. Exhalation: 1 micrometer particles reach bronchioles, 5 micrometer particles reach the larynx and 50 micrometer particles reach the mouth. A third torso shows porous particles: A porosity reaches alveoli, B porosity reaches lungs and C porosity reaches the mouth. Image B compares conventional atomized drugs with the HCLplga-Ab atomized platform. Conventional drugs interact with mucus and biofilm above the endothelium. The platform has two phases: phase one penetrates the mucus barrier and destroys biofilm, while phase two provides anti-inflammatory and antibacterial effects. Arrows show sequential drug release through respiratory tissue layers.Diagram: particle size/porosity impact lung deposition; HCLplga-Ab enhances drug delivery. Schematic illustration of a honeycomb-inspired porous microsphere as an inhalable drug delivery platform. (A) Particle deposition in the respiratory tract depends on aerodynamic size, which is tunable by adjusting microsphere porosity, enabling targeted lung delivery. (B) Sequential drug release: The inhalable dry powder aerosol penetrates the mucus barrier and disrupts biofilms during the first phase, followed by anti-inflammatory and antibacterial effects in the second phase.72 Reprinted with permission from Biomaterials, 322 (2025) 123401. Copyright 2025, with permission from Elsevier. To address metastatic lung cancer, porous PLGA microspheres fabricated via double emulsion/solvent evaporation were employed for the inhalational co-delivery of icariin (ICA) and miR-23b (Figure 9).73 These microspheres exhibited favorable aerodynamic properties, high drug loading and encapsulation efficiencies, and sustained release kinetics. Results demonstrated that porous PLGA microspheres serve as an effective inhalation platform for combined drug/gene delivery, highlighting their potential for treating lung cancer and other pulmonary diseases. Following inhalation, the microspheres directly deposited in lung tissue, achieving elevated local concentrations and controlled release, which enhanced therapeutic efficacy while minimizing systemic toxicity. Furthermore, the biodegradable and low-toxicity nature of PLGA underpins the safety and clinical feasibility of this system. This delivery strategy holds promise for developing novel therapeutic approaches against lung cancer and related respiratory disorders. Figure 9(A) Preparation and atomization of porous PLGA microspheres. Porous PLGA microspheres harboring icariin and PEI/miR-23b nanoparticles were prepared by double emulsification/solvent evaporation method. They could be well inhaled and deposited in the lungs after the proper aerolization, thereby obtaining favorable efficacy in the treatment of metastatic lung cancer. (B) H&E staining, Ki-67 and TUNEL immunofluorescence analysis, and IHC analysis of MMP-9 expression in melanoma metastatic lung tissue after treatment with different porous PLGA microspheres. Black scale bar: 100μm; White scale bar: 20μm. (C) Lung photos obtained from mice treated with different PLGA microspheres. (D) Relative area of melanoma nodules. Data were presented as mean ± SD (n = 4, n.d. not determined, **P < 0.01).73 Reprinted with permission from Asian Journal of Pharmaceutical Sciences, 20 (2025) 101008. Copyright 2025, with permission from Elsevier.Image A depicts an infographic of porous PLGA microspheres for inhalation delivery, highlighting components like PLGA, Icariin, miR-23b, PEI25K and processes such as cell death and targeting mRNA 3′ UTR. It includes terms like Caspase-8, Bcl-2, Caspase-9, Caspase-3, PARP and cell cycle phases G1, S, along with proliferation, invasion and migration. Image B shows lung tissue grids labeled Healthy, Untreated, Blank, PPM-1, PPM-2, PPM-3, with rows for H&E, Ki-67, TUNEL, MMP-9 and additional labels like Immunofluores, Cy3 plus DAPI, FITC plus DAPI, IHC. Image C arranges lung photos by health status and treatment. Image D presents a bar chart titled ′Relative area of nodules′ with categories Healthy, Untreated, Blank, PPM-1, PPM-2, PPM-3. The chart shows highest bars for Untreated and Blank, decreasing through PPM-1 to PPM-3, with significant differences marked between Blank and PPM-1 and PPM-1 and PPM-2.An infographic on inhaled PLGA microspheres and reduced lung nodule area across treatments. (A) Preparation and atomization of porous PLGA microspheres. Porous PLGA microspheres harboring icariin and PEI/miR-23b nanoparticles were prepared by double emulsification/solvent evaporation method. They could be well inhaled and deposited in the lungs after the proper aerolization, thereby obtaining favorable efficacy in the treatment of metastatic lung cancer. (B) H&E staining, Ki-67 and TUNEL immunofluorescence analysis, and IHC analysis of MMP-9 expression in melanoma metastatic lung tissue after treatment with different porous PLGA microspheres. Black scale bar: 100μm; White scale bar: 20μm. (C) Lung photos obtained from mice treated with different PLGA microspheres. (D) Relative area of melanoma nodules. Data were presented as mean ± SD (n = 4, n.d. not determined, **P < 0.01).73 Reprinted with permission from Asian Journal of Pharmaceutical Sciences, 20 (2025) 101008. Copyright 2025, with permission from Elsevier. Beyond lung cancer applications, inhalable swellable microspheres were explored for asthma therapy.74 The study developed a system for the concomitant pulmonary delivery of naringenin (NRG) and doxofylline (DOX). The formulation involved loading NRG onto glycerol tristearate-based solid lipid nanoparticles (NRG SLN), which were then co-encapsulated with DOX into chitosan-tripolyphosphate-based swellable microspheres (NRG SLN DOX sMS). Comprehensive characterization confirmed excellent swelling behavior and favorable aerodynamic properties. In a murine asthma model, the system significantly reduced serum bicarbonate levels and eosinophil counts while improving respiratory flow, tidal volume, and bronchial wall integrity compared to asthmatic controls. Collectively, this inhalable dual-drug platform represents a promising strategy for effective asthma management, offering a novel approach to co-deliver therapeutics locally, potentially enhancing efficacy while minimizing systemic side effects. Other researches on the treatment of lung diseases by inhalable microspheres were summarized in Table 3. Table 3Summary of Microspheres for Treating Pulmonary DiseasesDiseasesDrugsCarriersPreparation MethodsRemarksALI75Monoammoniuma GlycyrrhizinatePLGA microspheresElectrospray technologySlow release of drug reduced side effectsImproved therapeutic efficacyALI76Fibronectin (FN), resveratrol (Res)Core-shell microspheres (PLGA as shell, PCL-PEG micelles loading Res as core, FN modified on the surface)Electrospray technologyTarget macrophages through Arg-Gly-Asp peptide sequence of FNReduce inflammatory responsesScavenge excess ROSFacilitate mitochondrial homeostasis restorationLung cancer77DoxorubicinPCADK/PLGA mixed-matrix porous microspheresW/O/W emulsion methodAcid sensitivity and biodegradability enable high cumulative drug release and efficient deliveryPulmonary arterial hypertension78Aspirin derivative (ACS14, a H2S donor)PLGA based large porous microspheresMicrofluidic techniqueExcellent aerodynamic performance, with ideal drug loading and encapsulation efficiencySlow and continuous release of H2S alleviate symptomsPneumonia79Ginseng polysaccharidesPorous PLGA microspheresCompound emulsion solvent volatilization methodOvercoming the problems of low bioavailability and short half-life of polysaccharidesAchieving sustained releaseIPF80FormononetinChitosan-coated porous PLGA microspheresW/O/W emulsion solvent evaporation methodExhibiting long pulmonary retention because of the bio-adhesive property of chitosanNotes: All studies presented in this table are preclinical. Table 3Summary of Microspheres for Treating Pulmonary DiseasesDiseasesDrugsCarriersPreparation MethodsRemarksALI75Monoammoniuma GlycyrrhizinatePLGA microspheresElectrospray technologySlow release of drug reduced side effectsImproved therapeutic efficacyALI76Fibronectin (FN), resveratrol (Res)Core-shell microspheres (PLGA as shell, PCL-PEG micelles loading Res as core, FN modified on the surface)Electrospray technologyTarget macrophages through Arg-Gly-Asp peptide sequence of FNReduce inflammatory responsesScavenge excess ROSFacilitate mitochondrial homeostasis restorationLung cancer77DoxorubicinPCADK/PLGA mixed-matrix porous microspheresW/O/W emulsion methodAcid sensitivity and biodegradability enable high cumulative drug release and efficient deliveryPulmonary arterial hypertension78Aspirin derivative (ACS14, a H2S donor)PLGA based large porous microspheresMicrofluidic techniqueExcellent aerodynamic performance, with ideal drug loading and encapsulation efficiencySlow and continuous release of H2S alleviate symptomsPneumonia79Ginseng polysaccharidesPorous PLGA microspheresCompound emulsion solvent volatilization methodOvercoming the problems of low bioavailability and short half-life of polysaccharidesAchieving sustained releaseIPF80FormononetinChitosan-coated porous PLGA microspheresW/O/W emulsion solvent evaporation methodExhibiting long pulmonary retention because of the bio-adhesive property of chitosanNotes: All studies presented in this table are preclinical. Summary of Microspheres for Treating Pulmonary Diseases Slow release of drug reduced side effects Slow release of drug reduced side effects Improved therapeutic efficacy Improved therapeutic efficacy Target macrophages through Arg-Gly-Asp peptide sequence of FN Target macrophages through Arg-Gly-Asp peptide sequence of FN Reduce inflammatory responses Reduce inflammatory responses Scavenge excess ROS Scavenge excess ROS Facilitate mitochondrial homeostasis restoration Facilitate mitochondrial homeostasis restoration Acid sensitivity and biodegradability enable high cumulative drug release and efficient delivery Acid sensitivity and biodegradability enable high cumulative drug release and efficient delivery Excellent aerodynamic performance, with ideal drug loading and encapsulation efficiency Excellent aerodynamic performance, with ideal drug loading and encapsulation efficiency Slow and continuous release of H2S alleviate symptoms Slow and continuous release of H2S alleviate symptoms Overcoming the problems of low bioavailability and short half-life of polysaccharides Overcoming the problems of low bioavailability and short half-life of polysaccharides Achieving sustained release Achieving sustained release Exhibiting long pulmonary retention because of the bio-adhesive property of chitosan Exhibiting long pulmonary retention because of the bio-adhesive property of chitosan Notes: All studies presented in this table are preclinical. Biomimetic Platforms Biomimetic inhalation platforms are a class of inhalable formulations engineered through biomimetic strategies that mimic biological substances or structures, such as cell membranes or pulmonary surfactants. They are designed with optimized physicochemical properties, most notably a particle size ranging from 1 to 1000 nm. This size range facilitates effective lung deposition while enabling the particles to evade clearance by alveolar macrophages. A neutrophil membrane-modified inhalable nanoparticle (LVX@PLGA@Mem) was developed for the treatment of COPD (Figure 10).81 The nanocarrier was constructed by coating levofloxacin (LVX)-loaded PLGA nanoparticles with a neutrophil membrane, endowing it with mucus-penetrating, anti-inflammatory, and antibacterial capabilities. The membrane coating preserved most native proteins and functions. Its near-neutral surface charge reduced electrostatic repulsion with mucus, enhancing penetration of the mucosal barrier. Moreover, targeting proteins on the membrane enabled active migration to inflammatory sites, improving pulmonary drug distribution and retention. These nanoparticles also evaded immune cell phagocytosis, prolonging their circulation time. Experimental results demonstrated that this system effectively alleviated COPD symptoms by reducing pro-inflammatory cytokines, inflammatory immune cells, and bacterial load. Its unique combination of mucus penetration, anti-inflammatory, and antibacterial actions highlights its therapeutic potential for COPD. Furthermore, the nanoparticles exhibited good biocompatibility and low systemic toxicity, supporting their translational prospects. This work provides an innovative nanomedicine-based strategy for COPD management, with the potential to enhance therapeutic outcomes and patient compliance. Figure 10(A) Schematic diagram illustrating the fabrication process of LVX@PLGA@Mem. (B) its application for treatment of bacteria-infected COPD. (C) Representative images of bacterial colonies after different treatments. (D) H&E, Masson and AB-PAS images of lungs after different treatments.81 Reprinted with permission from Journal of Controlled Release, 381 (2025) 113648. Copyright 2025, with permission from Elsevier.The image A shows the fabrication process of LVX@PLGA@Mem. Neutrophils are activated with LPS, followed by cell membrane extraction. LVX and PLGA undergo sonication to form LVX@PLGA, which is coated with the neutrophil membrane to create LVX@PLGA@Mem. The image B illustrates the application of LVX@PLGA@Mem in the lungs, showing mucus, epithelium, bacteria and dead bacteria. Functions include cytokine neutralization, suppression of inflammation, antibiotic release and antibacterial activity. The image C displays bacterial colonies under different treatments: Healthy, COPD, COPD plus P.A., PBS, LVX@PLGA, PLGA@Mem and LVX@PLGA@Mem. The image D presents lung tissue images under different conditions: Healthy, COPD, COPD plus P.A. and treatments with PBS, LVX@PLGA, PLGA@Mem and LVX@PLGA@Mem. Tissue images include H&E, AB-PAS and Masson staining, with a scale of 500 micrometers.Composite image showing LVX@PLGA@Mem fabrication, lung treatment, bacterial colonies and lung tissue images. (A) Schematic diagram illustrating the fabrication process of LVX@PLGA@Mem. (B) its application for treatment of bacteria-infected COPD. (C) Representative images of bacterial colonies after different treatments. (D) H&E, Masson and AB-PAS images of lungs after different treatments.81 Reprinted with permission from Journal of Controlled Release, 381 (2025) 113648. Copyright 2025, with permission from Elsevier. Wang et al reported a synergistic inhalation strategy for IPF treatment using pulmonary surfactant-biomimetic liposomes (PSBs).82 The team designed PSBs composed of DPPC/POPG/DPPG/CHO to mimic natural pulmonary surfactant (PS) transport, co-loading the ROS scavenger astaxanthin (AST) and the anti-fibrotic drug pirfenidone (PFD) for precise aerosol delivery (Figure 11). Results demonstrated that PSBs, by fusing with the endogenous pulmonary surfactant membrane, efficiently targeted alveolar epithelial cells (AECs). Subsequently, released PFD penetrated the lung tissue barrier, significantly improving lung function, reducing collagen deposition and inflammatory factors, and promoting repair of damaged AECs in IPF mouse models. This study pioneers the use of the pulmonary surfactant recycling mechanism for cooperative drug delivery, offering a novel targeted platform for IPF. By optimizing PSB composition and delivery, this strategy may overcome the limited efficacy and systemic side effects of current anti-fibrotic drugs, presenting a potential clinical solution for IPF and informing new directions for inhaled therapies of other pulmonary diseases. Figure 11(A) Schematic diagram of the synergistic therapeutic effect of PSBs on IPF. After nebulization inhalation, PSBs gradually fuse with the PS layer, promoting the adsorption of AECs on AST. Simultaneously, PFD is released bypassing the PS barrier and effectively enters the lungs. (B) The anti-fibrotic effect of PSBs@AST/PFD on bleomycin-induced pulmonary fibrosis in mice. (C) The anti-fibrotic effect of PSBs@AST/PFD on silicosis-induced mice.82 Reprinted with permission from Biomaterials, 303 (2023) 122404. Copyright 2023, with permission from Elsevier.The image has three sections: A, B and C. Section A illustrates a nebulizer box with a mouse inhaling pulmonary surfactant-biomimetic liposomes (PSBs), alongside an alveoli diagram. Arrows show clearance to alveolar macrophages, surfactant circulation through alveolar epithelial cell II and repair pathways. Labels include Nebulizer box, Clearance, Pulmonary Surfactant Circulation, Alveolar Macrophages, Pulmonary Surfactant, AEC I, AEC II, PSBs, Prifenidone, Astaxanthin and Common Liposomes. Section B displays lung tissue sections with magnified insets for six conditions: Normal, BLM, PFD, TLs/PFD at AST, PLs/PFD at AST and PSBs/PFD at AST. Normal tissue has open alveolar spaces; BLM shows dense staining. PSBs/PFD at AST insets reveal more open spaces. Section C mirrors this layout for: Normal, SiO2, PFD, TLs at AST/PFD, PLs at AST/PFD and PSBs at AST/PFD, showing similar tissue density differences across conditions.Composite scientific figure with one schematic and two rows of lung histology images across six conditions each. (A) Schematic diagram of the synergistic therapeutic effect of PSBs on IPF. After nebulization inhalation, PSBs gradually fuse with the PS layer, promoting the adsorption of AECs on AST. Simultaneously, PFD is released bypassing the PS barrier and effectively enters the lungs. (B) The anti-fibrotic effect of PSBs@AST/PFD on bleomycin-induced pulmonary fibrosis in mice. (C) The anti-fibrotic effect of PSBs@AST/PFD on silicosis-induced mice.82 Reprinted with permission from Biomaterials, 303 (2023) 122404. Copyright 2023, with permission from Elsevier. The field of biomimetic inhalation for pulmonary disease therapy continues to advance with innovative delivery technologies. By mimicking endogenous substances or structures, inhalable formulations with tailored properties can be engineered to achieve targeted delivery and synergistic effects. Concurrently, cell-derived platforms are expanding the scope of this approach. For instance, the clinical potential of nebulized extracellular vesicles from human umbilical cord mesenchymal stem cells (hUCMSC-EVs) for treating pulmonary fibrosis was evaluated.83 Through a rigorous quality control system, high-quality hUCMSC-EVs were produced and comprehensively characterized by miRNA, protein, and metabolite profiles. In murine models, nebulized hUCMSC-EVs predominantly accumulated in the lungs, markedly ameliorating bleomycin-induced fibrosis: survival increased from 20% to 80%, lung volume recovered, tissue damage was alleviated, and oxygenation and lung function improved. A subsequent Phase I trial involving 24 randomized patients demonstrated good tolerance to nebulized hUCMSC-EVs with no serious adverse events. Patients receiving hUCMSC-EVs combined with standard care showed significant improvements in lung function and respiratory health. Notably, two patients with advanced post-inflammatory fibrosis exhibited marked regression on serial CT scans (Figure 12). These findings indicate the potential of nebulized hUCMSC-EVs as a novel therapeutic strategy for pulmonary fibrosis. However, further large-scale trials are warranted to confirm their long-term safety and efficacy. Other researches on the treatment of lung diseases by inhalable biomimetic nanoparticles were summarized in Table 4. Figure 12(A) Process roadmap for the preparation of hUCMSC-EVs. (B) Representative histological lung sections of mice stained with H&E and Masson trichrome 21 days after injury. (C) Representative HRCT images of the lungs of three participants.83 Reprinted with permission from Signal Transduction and Targeted Therapy, 10 (2025) 179. Copyright 2025, with permission from Springer Nature.The image A shows a workflow diagram for hUCMSC-EV preparation. UCMSCs P4 working bank cells are cultured and EVs in media are collected at quality control checkpoint 2. Sequential centrifugation steps follow: 800g for 5 min removing cells, 2000g for 10 min removing dead cells, 10,000g for 30 min removing cell debris, then 110,000g for 1.5 hours for EV purification. The pellet is washed with 50 milliliter PBS and resuspended. EVs display markers CD9, CD63 and CD81. Final quality control checkpoint 4 yields GMP-compliant EVs for patient nebulization using a nebulizer with 2 micrometer aperture mesh and protein and RNA analysis. The image B shows histological lung sections with H&E and Masson stains across four groups: Ctrl, Saline, L929 EVs and UC EVs. The image C shows HRCT lung images for Part icipant 9 and Part icipant 15 treated with hUCMSC-EVs and Part icipant 18 treated with saline, at timepoints D0, D28 and D84, with arrows marking specific lung regions.Scientific figure: hUCMSC-EV prep, lung histology, longitudinal CT scans. Table 4Summary of Inhalable Biomimetic Nanoparticles for Treating Pulmonary DiseasesDiseasesActive IngredientsBiomimetic ComponentsRemarksNeutrophilic asthma84Luminol-conjugated α-cyclodextrin NPsNeutrophil cell membranesSurface engineering via neutrophil cell membrane enhanced targeting and therapeutic effectsIPF85PFD-loaded nanovesiclesPulmonary surfactantPulmonary surfactant coating improved the efficiency of drug deliveryProlonged the retention time of drugAsthma86BudesonideCarbonized ganoderma lucidum spores (cGLS)The natural morphology of cGLS reduced immune responseEnhanced pulmonary retentionIncreased drug-loading capacityALI87Small RNAs (siMyd88)Small extracellular vesicles (sEVs)Natural sEVs protect small RNAs from degradation and enzymatic digestionEnsuring stability and enabling precise targeted delivery to specific lung cellsALI88ROS-scavenging and pro-inflammatory cytokine-neutralizing hydrogel microparticles (HBPAK HMPs)Inflammatory macrophage (M1) cell membranesCell membrane coating helped HMPs evade the clearance by immune systemEnhanced the ROS clearance and anti-inflammatory propertiesNotes: All studies presented in this table are preclinical. (A) Process roadmap for the preparation of hUCMSC-EVs. (B) Representative histological lung sections of mice stained with H&E and Masson trichrome 21 days after injury. (C) Representative HRCT images of the lungs of three participants.83 Reprinted with permission from Signal Transduction and Targeted Therapy, 10 (2025) 179. Copyright 2025, with permission from Springer Nature. Table 4Summary of Inhalable Biomimetic Nanoparticles for Treating Pulmonary DiseasesDiseasesActive IngredientsBiomimetic ComponentsRemarksNeutrophilic asthma84Luminol-conjugated α-cyclodextrin NPsNeutrophil cell membranesSurface engineering via neutrophil cell membrane enhanced targeting and therapeutic effectsIPF85PFD-loaded nanovesiclesPulmonary surfactantPulmonary surfactant coating improved the efficiency of drug deliveryProlonged the retention time of drugAsthma86BudesonideCarbonized ganoderma lucidum spores (cGLS)The natural morphology of cGLS reduced immune responseEnhanced pulmonary retentionIncreased drug-loading capacityALI87Small RNAs (siMyd88)Small extracellular vesicles (sEVs)Natural sEVs protect small RNAs from degradation and enzymatic digestionEnsuring stability and enabling precise targeted delivery to specific lung cellsALI88ROS-scavenging and pro-inflammatory cytokine-neutralizing hydrogel microparticles (HBPAK HMPs)Inflammatory macrophage (M1) cell membranesCell membrane coating helped HMPs evade the clearance by immune systemEnhanced the ROS clearance and anti-inflammatory propertiesNotes: All studies presented in this table are preclinical. Summary of Inhalable Biomimetic Nanoparticles for Treating Pulmonary Diseases Surface engineering via neutrophil cell membrane enhanced targeting and therapeutic effects Surface engineering via neutrophil cell membrane enhanced targeting and therapeutic effects Pulmonary surfactant coating improved the efficiency of drug delivery Pulmonary surfactant coating improved the efficiency of drug delivery Prolonged the retention time of drug Prolonged the retention time of drug The natural morphology of cGLS reduced immune response The natural morphology of cGLS reduced immune response Enhanced pulmonary retention Enhanced pulmonary retention Increased drug-loading capacity Increased drug-loading capacity Natural sEVs protect small RNAs from degradation and enzymatic digestion Natural sEVs protect small RNAs from degradation and enzymatic digestion Ensuring stability and enabling precise targeted delivery to specific lung cells Ensuring stability and enabling precise targeted delivery to specific lung cells Cell membrane coating helped HMPs evade the clearance by immune system Cell membrane coating helped HMPs evade the clearance by immune system Enhanced the ROS clearance and anti-inflammatory properties Enhanced the ROS clearance and anti-inflammatory properties Notes: All studies presented in this table are preclinical. Others Beyond the prominent roles played by nanoparticles, liposomes, microspheres, and biomimetic preparations in treating pulmonary diseases, other innovative inhalation strategies continue to emerge, such as gel-based and dry powder inhalers (DPIs). These systems enrich the repertoire of inhalation formulations, offering novel therapeutic perspectives. Gel-based inhalers can enhance bioavailability and reduce systemic side effects. Through specific preparation methods, they can be engineered to possess multi-stimuli responsiveness, as well as synergistic antioxidant and anti-inflammatory efficacy.89–91 DPIs often prepared via technologies like spray drying, address challenges related to drug stability, hepatic metabolism, and oral bioavailability. They facilitate direct drug deposition in the deep lung, thereby improving local bioavailability and minimizing systemic risks.92–94 Furthermore, innovative formulations such as inclusion complexes and advanced aerosol systems contribute multi-faceted therapeutic effects. Collectively, these developments inject new vitality into pulmonary disease treatment and broaden the development pathways for novel inhalation therapies. The details were summarized in Table 5. Table 5Summary of Other Inhalation Preparations for Treating Pulmonary DiseasesDiseasesPreparationsComponentsRemarksIPF95MicrogelsNintedanib-PLGA NPs and PFD-liposomesProlonged and enhanced anti-fibrotic effectsAlveolar macrophage phagocytosis-evadingALI96NanogelsCurcumin-alginate nanogelsMulti-stimulus (temperature, pH, ions) sensitiveImproved bioavailability of curcuminCOPD97Dry powderCannabidiol (CBD), inulin, L-leucine,The formulations and process of CBD dry powder was optimizedThe bioavailability of CBD was improvedCOPD98Dry powderOsteoglycin fragment, inulin, mannitol, leucineInulin shows advantages in improving the stability, dispersibility, aerodynamic properties of dry powderAsthma99Dry powderAnandamide-loaded amphiphilic cyclodextrin NPs, mannitolHigh drug loading capacityGood re-dispersibility and stabilityALI100Inclusion complexesQuercetin-β-cyclodextrin inclusion complexesSupercritical antisolvent process endows accelerated drug release, high lung deposition and enhanced therapeutic efficiencyIPF (NCT02257177)101Dry powderTD139 (potent small-molecule inhibitor of Gal-3)TD139 concentration-dependently inhibits Gal-3 surface expression on alveolar macrophages. It reduces plasma biomarkers linked to IPF progression Drug concentrations in the lungs markedly exceed those in plasma, indicating good pulmonary retentionCOPD (NCT07140328)102Dry powderInhalation suspensionHSK39004HSK39004 simultaneously inhibit the activity of both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4)Directly delivering HSK39004 to lung lesions, increasing local drug concentration, enhancing efficacy, and reducing systemic side effectsCOPD (NCT07633314)103Inhalation aerosolTQC3927Rapid onset of action, low dosage, fewer adverse reactions, convenient administrationSynergistic effect of dual LABA/LAMA targetingIPF (NCT07344558)104Dry powderNintedanibDirect pulmonary delivery minimizing the systemic side effects caused by oral administrationNotes: Studies with a clinical trial number provided are clinical studies; those without are preclinical studies. Table 5Summary of Other Inhalation Preparations for Treating Pulmonary DiseasesDiseasesPreparationsComponentsRemarksIPF95MicrogelsNintedanib-PLGA NPs and PFD-liposomesProlonged and enhanced anti-fibrotic effectsAlveolar macrophage phagocytosis-evadingALI96NanogelsCurcumin-alginate nanogelsMulti-stimulus (temperature, pH, ions) sensitiveImproved bioavailability of curcuminCOPD97Dry powderCannabidiol (CBD), inulin, L-leucine,The formulations and process of CBD dry powder was optimizedThe bioavailability of CBD was improvedCOPD98Dry powderOsteoglycin fragment, inulin, mannitol, leucineInulin shows advantages in improving the stability, dispersibility, aerodynamic properties of dry powderAsthma99Dry powderAnandamide-loaded amphiphilic cyclodextrin NPs, mannitolHigh drug loading capacityGood re-dispersibility and stabilityALI100Inclusion complexesQuercetin-β-cyclodextrin inclusion complexesSupercritical antisolvent process endows accelerated drug release, high lung deposition and enhanced therapeutic efficiencyIPF (NCT02257177)101Dry powderTD139 (potent small-molecule inhibitor of Gal-3)TD139 concentration-dependently inhibits Gal-3 surface expression on alveolar macrophages. It reduces plasma biomarkers linked to IPF progression Drug concentrations in the lungs markedly exceed those in plasma, indicating good pulmonary retentionCOPD (NCT07140328)102Dry powderInhalation suspensionHSK39004HSK39004 simultaneously inhibit the activity of both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4)Directly delivering HSK39004 to lung lesions, increasing local drug concentration, enhancing efficacy, and reducing systemic side effectsCOPD (NCT07633314)103Inhalation aerosolTQC3927Rapid onset of action, low dosage, fewer adverse reactions, convenient administrationSynergistic effect of dual LABA/LAMA targetingIPF (NCT07344558)104Dry powderNintedanibDirect pulmonary delivery minimizing the systemic side effects caused by oral administrationNotes: Studies with a clinical trial number provided are clinical studies; those without are preclinical studies. Summary of Other Inhalation Preparations for Treating Pulmonary Diseases Prolonged and enhanced anti-fibrotic effects Prolonged and enhanced anti-fibrotic effects Alveolar macrophage phagocytosis-evading Alveolar macrophage phagocytosis-evading Multi-stimulus (temperature, pH, ions) sensitive Multi-stimulus (temperature, pH, ions) sensitive Improved bioavailability of curcumin Improved bioavailability of curcumin The formulations and process of CBD dry powder was optimized The formulations and process of CBD dry powder was optimized The bioavailability of CBD was improved The bioavailability of CBD was improved Inulin shows advantages in improving the stability, dispersibility, aerodynamic properties of dry powder Inulin shows advantages in improving the stability, dispersibility, aerodynamic properties of dry powder High drug loading capacity High drug loading capacity Good re-dispersibility and stability Good re-dispersibility and stability Supercritical antisolvent process endows accelerated drug release, high lung deposition and enhanced therapeutic efficiency Supercritical antisolvent process endows accelerated drug release, high lung deposition and enhanced therapeutic efficiency TD139 concentration-dependently inhibits Gal-3 surface expression on alveolar macrophages. It reduces plasma biomarkers linked to IPF progression TD139 concentration-dependently inhibits Gal-3 surface expression on alveolar macrophages. It reduces plasma biomarkers linked to IPF progression Drug concentrations in the lungs markedly exceed those in plasma, indicating good pulmonary retention Drug concentrations in the lungs markedly exceed those in plasma, indicating good pulmonary retention HSK39004 simultaneously inhibit the activity of both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) HSK39004 simultaneously inhibit the activity of both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) Directly delivering HSK39004 to lung lesions, increasing local drug concentration, enhancing efficacy, and reducing systemic side effects Directly delivering HSK39004 to lung lesions, increasing local drug concentration, enhancing efficacy, and reducing systemic side effects Rapid onset of action, low dosage, fewer adverse reactions, convenient administration Rapid onset of action, low dosage, fewer adverse reactions, convenient administration Synergistic effect of dual LABA/LAMA targeting Synergistic effect of dual LABA/LAMA targeting Direct pulmonary delivery minimizing the systemic side effects caused by oral administration Direct pulmonary delivery minimizing the systemic side effects caused by oral administration Notes: Studies with a clinical trial number provided are clinical studies; those without are preclinical studies. Discussion Although inhalation platforms hold great promise, their clinical translation still faces a series of critical hurdles that call for a more balanced and in-depth examination. Beyond the requirements of precise delivery to diseased lung regions, several other core bottlenecks (eg., dependence on device handling, limited pulmonary retention time) in the translation process are often underestimated. Variability in airway deposition, influenced by breathing patterns, airway geometry, and disease state, leads to unpredictable dose distribution. Meanwhile, the viscous mucus barrier, rapid mucociliary clearance, and phagocytic clearance by alveolar macrophages further shorten the effective residence time of the drug at the target site. Differences in inhaler device design and inadequate patient adherence frequently cause significant deviations between the actual delivered dose and the intended dose, exacerbating uncertainty in therapeutic efficacy. In terms of long-term safety, greater vigilance is required for risks that may emerge after repeated administration, such as cumulative toxicity, immunogenicity, excessive nanocarrier burden on alveolar macrophages, local irritation, and even chronic lung injury. These factors constitute major barriers to bench-to-bedside translation. Notably, nanoscale inhaled formulations have entered the market recently, providing an important window for evaluating the real-world performance of such platforms. For example, amikacin liposome inhalation suspension has demonstrated targeted therapeutic advantages in refractory pulmonary mycobacterial infections. However, its clinical application has also revealed potential concerns such as local irritation (eg., coughing, hemoptysis) and long-term lipid loading in macrophages,105–107 indicating that even marketed products still have room for improvement in delivery efficiency, mucus penetration, and long-term safety. Moreover, scaling up nano-inhaled formulations from the laboratory to industrial production is extremely challenging. It requires precise control of particle size, drug loading, and release behavior under large-scale conditions, while ensuring batch-to-batch consistency and sterility requirements. Processes such as spray drying and microfluidics are prone to particle aggregation, degradation, or polymorphic transformation during scale-up, creating another barrier to product translation. Conclusion and Prospect Pulmonary diseases, including COPD, asthma, pneumonia, pulmonary fibrosis, and lung cancer, present a serious threat to human health. While conventional therapies have certain limitations, inhalation formulations have emerged as an effective strategy for the treatment of these conditions, owing to their ability to achieve uniform lung distribution, rapid onset of action, high bioavailability, and avoidance of hepatic first-pass metabolism. This article reviews recent advances in novel inhalation drug delivery systems, with a focus on cutting-edge formulations such as nanoparticles, liposomes, microspheres, and biomimetic inhalers. By leveraging nanotechnology, advanced carrier materials, and biomimetic strategies, these novel systems significantly enhance drug stability, lung deposition efficiency, and targeting capability. They can also effectively overcome physiological barriers such as mucus, achieve sustained and controlled drug release, and ultimately improve therapeutic outcomes while reducing dosing frequency. Furthermore, other innovative inhalation platforms, including gel-based formulations, continue to broaden the scope and potential of inhalation therapy. Despite their promising prospects, the clinical translation of inhalation formulations still faces several challenges. However, technological advancements, significant clinical demand, the rise of personalized medicine, and supportive regulatory policies collectively provide strong momentum for the innovation and clinical adoption of these systems. Looking ahead, the future development of inhalation therapy will achieve breakthroughs by deeply integrating nanoengineering, biomimetic design, and smart devices, building on existing experience and lessons from current obstacles. To overcome bottlenecks such as the mucus barrier, macrophage phagocytosis, and rapid mucociliary clearance, cell membrane-coated nanoparticles, exosome-based carriers, and smart nanosystems capable of sensing the pathological microenvironment and releasing drugs in response are expected. Smart inhaler devices need to be deeply integrated with formulation properties to address variability in patient handling. By recognizing breathing patterns in real time and providing feedback, they will ensure controllable aerosol deposition even in the presence of variations in airway geometry, truly establishing an integrated “device-formulation-patient” precision delivery system. At the industrialization level, the combination of continuous spray drying, highly reproducible microfluidic processes, and AI-driven process analytical technology will effectively overcome the core challenges, thereby supporting the commercial translation of personalized inhalation regimens. On this basis, inhalation therapy is poised to progress from broad-spectrum drug delivery to intelligent, personalized targeted interventions against specific pathological microenvironments in diseases, ultimately reshaping the overall landscape of pulmonary disease treatment. Notably, the application scope of inhalation delivery is expanding beyond pulmonary conditions, demonstrating considerable potential for treating systemic diseases (eg., diabetes,108,109 Parkinson’s disease110,111), intervening in central nervous system disorders (eg., depression, anxiety),112,113 and even enabling novel approaches in cell therapy and other cutting-edge areas.114–117 In summary, the ongoing development and innovation of advanced inhalation formulations are poised not only to transform the clinical management of lung diseases but also to open new therapeutic avenues for a broader range of disorders, ultimately benefiting a larger patient population worldwide.